Hopkins team develops first mouse model of schizophrenia

Johns Hopkins researchers have genetically engineered the first mouse that models both the anatomical and behavioral defects of schizophrenia, a complex and debilitating brain disorder that affects over 2 million Americans.

In contrast to current animal studies that rely on drugs that can only mimic the manifestations of schizophrenia, such as delusions, mood changes and paranoia, this new mouse is based on a genetic change relevant to the disease. Thus, this mouse should greatly help with understanding disease progression and developing new therapies.

Animal models of schizophrenia have been hard to design since many different causes underlie this disease. However, Akira Sawa, M.D., Ph.D., associate professor of psychiatry and neuroscience and director of the program in molecular psychiatry and his colleagues took advantage of the recent discovery of a major risk factor for this disease: the DISC1 gene (short for disrupted in schizophrenia), which makes a protein that helps nerve cells assume their proper positions in the brain.

As reported online this week in Proceedings of the National Academy of Sciences, the researchers generated mice that make an incomplete, shortened form of the DISC1 protein in addition to the regular type. The short form of the protein attaches to the full-length one, disrupting its normal duties.

As these mice matured, they became more agitated when placed in an open field, had trouble finding hidden food, and did not swim as long as regular mice; such behaviors parallel the hyperactivity, smell defects and apathy observed in schizophrenia patients. Magnetic resonance imaging (MRI), taken in collaboration with Susumu Mori, Ph.D., professor of radiology, also revealed characteristic defects in brain structure, including enlarged lateral ventricles, a region that circulates the spinal fluid and helps protect against physical trauma.

Sawa notes that the defects in these mice were not as severe as those typically seen in people with schizophrenia, because more than one gene is required to trigger the clinical disease. “However, this mouse model will help us fill many gaps in schizophrenia research,” he says. “We can use them to explore how external factors like stress or viruses may worsen symptoms. The animals can also be bred with other strains of genetically engineered mice to try to pinpoint additional schizophrenia genes.”

Source: Johns Hopkins Medical Institutions

Related stories:

Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs
Researchers at Columbia University Medical Center have illuminated a window into how abnormalities in microRNAs, a family of molecules that regulate expression of numerous genes, may contribute to the behavioral and neuronal deficits associated with schizophrenia and possibly other brain disorders.
Researchers discover new link to schizophrenia
Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors. The finding raises the possibility that this enzyme may participate in the development of schizophrenia and related psychiatric disorders and therefore may provide a new target for developing therapies.
Scientists offer insight into how the nervous system processes sensory information
The Stowers Institute’s Yu Lab has published the results of large-scale imaging experiments examining how social signals are represented in the sensory system.
Brain scientist shedding light on learning, memory
Neurons spoke to Dr. Joe Z. Tsien when he was a sophomore college student searching for some meaningful extracurricular activity.
New treatment mechanisms for schizophrenia
The field of schizophrenia research has come alive with many exciting new potential approaches to treatment. From the introduction of chlorpromazine to the current day, all treatments approved by the U.S. Food and Drug Administration have had, at their core, a single treatment mechanism, the blockade of the dopamine D2 receptor.
Knowing how ketamine impairs brain circuitry may lead to new therapies for schizophrenia
Scientists know that the drug ketamine – street name “Special K” – can induce schizophrenia-like symptoms in drug abusers. Ketamine is also used as an anesthetic and, more recently, as an antidepressant – raising concerns by researchers at the University of California, San Diego (UCSD) School of Medicine, who have found that ketamine leads to the impairments in brain circuitry observed in both drug abusers and schizophrenic patients by causing increased production of a toxic free radical called “superoxide.” Their findings, which could point the way to novel treatments for schizophrenia, will be published in the December 7 issue of the journal Science.
Mitochondria defects linked to social behavior and spatial memory
Respiration deficiencies in mitochondria, the cell’s powerhouses, are associated with changed social behavior and spatial memory in laboratory mice, report scientists at the American Society for Cell Biology 47th Annual Meeting.
Imaging neural progenitor cells in the living human brain
For the first time, investigators have identified a way to detect neural progenitor cells (NPCs), which can develop into neurons and other nervous system cells, in the living human brain using a type of imaging called magnetic resonance spectroscopy (MRS). The finding, supported by the National Institutes of Health (NIH), may lead to improved diagnosis and treatment for depression, Parkinson's disease, brain tumors, and a host of other disorders.

News discussion:

Medicine & Health news